Arthex Biotech is in search of funding, to continue growing. The Spanish biotech company specializing in the treatment of diseases with unmet medical needs is seeking more than €13 million from the European Commission (EC) to continue its research.
The Valencian company has obtained a grant, in the form of non-dilutive funding, of €2.5 million from the EC under the EIC Accelerator. The company will also be eligible for an injection of more than eleven million euros from EIC’s own investment fund.
The Valencian biotech will receive training and mentoring on access to investments, large companies, and other services related to business acceleration from the EIC community.
Thanks to the resources obtained by the company, it will be able to continue advancing in the development of its main product, the drug ATX-01, aimed at treating myotonic dystrophy type 1 (DM1), a severe disease with no known cure or drug treatment currently available. It is a rare muscular dystrophy.
Read more about Arthex Biotech and find other important news with our companion app. Get the latest biotechnology news at your fingertips. Discover what is new in biotech research, finance, business, and more with Born2Invest. Our companion app includes news updates of finance headlines from fin-tech to investing and cannabis.
Arthex Biotech was born in 2019 and was backed by Invivo Ventures, which committed €2.7 million
Arthex Biotech is a spin-off of the University of Valencia (UV). Incorporated in September 2019, the company has its focus on the development of a treatment for myotonic dystrophy based on antisense RNA therapies for the treatment of DM1.
Researchers Rubén Artero and Beatriz Llamusí founded the company, with the support of Invivo Ventures capital, which committed €2.7 million, so that an RNA therapy developed by UV’s translational genomics research group and the Incliva Health Research Institute could reach DM1 patients.
In 2020, the company closed a €4.2 million financing round that was led by the fund specializing in the life sciences sector Advent France Biotechnology (AFB) and Invivo Ventures, a Barcelona-based venture capital manager.
Last August, the U.S. Food and Drug Administration (FDA) designated ATX-01 as an orphan drug. DM1 is a highly disabling disease that affects more than one million people worldwide. The condition affects muscles and other tissues and most often manifests itself during advanced age, although it can develop at birth in congenital form or during childhood.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [++ KuCoin Affiliate Program Review]
This week, we answer the two questions on everyone’s lips — What do SJWs and e/accs have in common? And...
BIPV Boom: By 2032, Building Integrated Photovoltaics Will Be Worth Over $143B
The next moves by the European Commission and the trend toward a real estate stock composed of Zero Emission Buildings...
French Fintech Company Qonto Launches SME Financing in Italy
Qonto is expanding its financial solutions for SMEs and professionals in Europe, launching the option for companies in Italy to...
Trusters and Leone Investments Finally Receive Approval Under EU Regulation
After almost a month under the new EU Regulation, two platforms, including the historic Trusters launched in 2018 and the...
Coinbase Wallet Has a New Feature: Send Crypto via Web Link
The exciting part is actually in the small print: This is because Coinbase covers the fees for transactions via stablecoin...
Cannabis2 weeks ago
The Illegal Cannabis Market in Europe Reaches €11.4 Billion
Impact Investing1 week ago
Why the Carbon Credit Market Is Not Working
Cannabis2 weeks ago
Germany Plans to Legalize Home Cultivation and Possession of Cannabis as of April 1st, 2024
Impact Investing4 days ago
ESG Investing Is About Getting It Right Over the Long Term Without Losing Profitability